Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Gets Price Target Cut from Truist Financial

Key Points

• Truist Financial lowered its price target for Fresenius Medical Care from $25 to $24 while maintaining a “hold” rating, implying approximately 13.1% upside from the prior close.
• Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating and an average price target of $23.42, with eight Hold and five Sell ratings.
• Fresenius Medical Care recently exceeded quarterly expectations, reporting $0.66 in EPS versus $0.62 expected and $5.55 billion in revenue versus $5.48 billion forecast; shares were trading near $21.21.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) had its price target lowered by investment analysts at Truist Financial from $25.00 to $24.00 in a research report issued on Monday, Benzinga reports. The firm currently has a "hold" rating on the stock. Truist Financial's price objective would indicate a potential upside of 13.13% from the company's previous close.

Several other research firms also recently commented on FMS. Citigroup reiterated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a "strong sell" rating to a "hold" rating in a research report on Monday, July 6th. Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Finally, BNP Paribas Exane cut shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 target price on the stock. in a research note on Tuesday, July 28th. Eight analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA stock traded up $0.15 during mid-day trading on Monday, hitting $21.21. 503,225 shares of the company's stock traded hands, compared to its average volume of 709,553. The stock has a market cap of $11.40 billion, a price-to-earnings ratio of 10.99, a P/E/G ratio of 3.85 and a beta of 0.74. The firm has a 50 day simple moving average of $22.92 and a two-hundred day simple moving average of $22.91. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.54.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.04. The company had revenue of $5.55 billion during the quarter, compared to analysts' expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. On average, research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.28 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently made changes to their positions in FMS. Moran Wealth Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company's stock worth $7,846,000 after buying an additional 83,311 shares in the last quarter. Tidal Investments LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 96.0% during the 2nd quarter. Tidal Investments LLC now owns 99,790 shares of the company's stock worth $2,256,000 after purchasing an additional 48,885 shares during the period. Royal Bank of Canada grew its position in Fresenius Medical Care AG & Co. KGaA by 479.2% during the first quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock valued at $4,893,000 after buying an additional 179,418 shares during the period. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% during the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company's stock worth $339,592,000 after buying an additional 299,986 shares during the period. Finally, Ritholtz Wealth Management increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 252.7% during the first quarter. Ritholtz Wealth Management now owns 84,658 shares of the company's stock worth $1,910,000 after purchasing an additional 60,652 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.